Learn more about our policy experts.

Media Contacts

Angela Bradbery, Director of Communications
w. (202) 588-7741
c. (202) 503-6768
abradbery@citizen.org, Twitter

Don Owens, Deputy Director of Communications
w. (202) 588-7767
dowens@citizen.org

Karilyn Gower, Press Officer
w. (202) 588-7779
kgower@citizen.org

David Rosen, Press Officer, Regulatory Affairs
w. (202) 588-7742
drosen@citizen.org

Other Important Links

Press Release Database
Citizen Vox blog
Texas Vox blog
Consumer Law and Policy blog
Energy Vox blog
Eyes on Trade blog
Facebook/publiccitizen

Follow us on Twitter

 

Dec. 7, 2010 
 
FDA Must Not Approve Another Dangerous Weight Loss Drug

Statement of Dr. Sidney Wolfe, Director, Public Citizen’s Health Research Group

 An advisory committee for the Food and Drug Administration (FDA) will weigh approval of another weight loss drug today – and the agency must reject it.

 The diet pill Contrave is the latest in a long line of dangerous and, ultimately, failed weight loss drugs. All of the following drugs, once approved for weight reduction, had severe cardiovascular side effects and were later either banned or de-listed for weight loss: thyroid hormone, amphetamine, fenfluramine/dexfenfluramine (also known as fen-phen), phenlylpropanolamine (PPA), ephedra and sibutramine (also known as Meridia).

 Contrave, manufactured by Orexigen Therapeutics, has shown to worsen key cardiovascular risk factors, including increased blood pressure, heart rate and palpitations, which nullify the cardiovascular benefit of weight loss in these patients.

 Additionally, the drug is expected to cause seizures. With millions of new people likely to receive this drug, if approved, this could represent an enormous burden of new disease.

 To further increase the cardiovascular and other health risks of these obese patients – who are already vulnerable to cardiovascular disease – is unacceptable. The FDA advisory committee and the agency as a whole should reject the approval of Contrave. The fact that one of its ingredients, bupropion, was previously known to cause increased blood pressure – an unequivocal risk factor for heart attacks and strokes – makes the attempt to study and approve this drug unethical.

 To read the full remarks presented to the FDA advisory committee on Contrave, visit: http://www.citizen.org/hrg1922.

###
Public Citizen is a national, nonprofit consumer advocacy organization based in Washington, D.C. For more information, please visit www.citizen.org.

Copyright © 2016 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.


Public Citizen, Inc. and Public Citizen Foundation

 

You can support the fight for greater government and corporate accountability through a donation to either Public Citizen, Inc., or Public Citizen Foundation, Inc.

Public Citizen lobbies Congress and federal agencies to advance Public Citizen’s mission of advancing government and corporate accountability. When you make a contribution to Public Citizen, you become a member of Public Citizen, showing your support and entitling you to benefits such as Public Citizen News. Contributions to Public Citizen are not tax-deductible.

Public Citizen Foundation focuses on research, public education, and litigation in support of our mission. By law, the Foundation can engage in only very limited lobbying. Contributions to Public Citizen Foundation are tax-deductible.